BridgeBio Pharma, Inc. — Director's Dealing 2020

Jun 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-06-03

Reporting Person: YAU YI CHING (Chief Accounting Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-03	Stock Option (Right to Buy)	$28.86	A	45931	Acquired	2030-06-02	Common Stock (45931)	Direct
2020-06-03	Restricted Stock Units	$	A	6383	Acquired		Common Stock (6383)	Direct

Footnotes

F1: The Option will vest over approximately four years. 1/48th of the shares of Common Stock underlying the Option will vest on a monthly basis after June 3, 2020 (the "Vesting Commencement Date"), such that all of the shares underlying the Option will be vested on the date four (4) years after the Vesting Commencement Date, subject to the Reporting Person's continued Service Relationship (as defined in the Plan) with the Issuer or any of its subsidiaries through the applicable vesting date.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date.